Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIVIGAM in Pediatric PIDD
NCT03164967Phase 4Completed
- Sponsor
- ADMA Biologics, Inc.
- Start
- Dec 2016
- Primary completion
- Aug 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of polyvalent human immunoglobulin in primary immunodeficiency disorder (PID), sponsored by ADMA Biologics, Inc.. Started Dec 2016; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disorder (PID)
Beyond the preview
Go deeper on NCT03164967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164967.